Your session is about to expire
What is Lonox
EnoxaparinThe Generic name of this drug
Treatment SummaryEnoxaparin is a type of low-molecular-weight heparin (LMWH) used to treat and prevent blood clots. It was approved by the FDA in 1993 and is administered through an injection, either subcutaneously or intravenously. Enoxaparin has been found to be more effective than unfractionated heparin in reducing the risk of venous thromboembolism, while also not increasing the risk of serious bleeding.
Lovenoxis the brand name
Lonox Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Lovenox
Enoxaparin
1993
183
Approved as Treatment by the FDA
Enoxaparin, also known as Lovenox, is approved by the FDA for 6 uses like Inpatients and General Surgery .Inpatients
General Surgery
Immobility
Deep Vein Thrombosis
Acute Chest Syndrome
Helps manage Acute Coronary Syndrome (ACS)
Outpatients
Effectiveness
How Lonox Affects PatientsEnoxaparin is a drug that works quickly and helps to prevent and reduce blood clots and heart issues. Research has shown that enoxaparin is more effective than heparin at preventing blood clots, and that when taken every 12 hours, it can cause an increase in blood tests (TT and aPTT) by 16%. It is important to be aware that there is an increased risk of bleeding and low blood platelet count when taking enoxaparin, as well as a higher risk of blood clots for pregnant women with artificial heart valves.
How Lonox works in the bodyEnoxaparin is an anticoagulant drug that prevents the formation of blood clots. It works by binding to a molecule called antithrombin III, which stops the formation of an enzyme called factor Xa. This prevents the formation of a clot, which helps to prevent thromboembolic events. Enoxaparin also directly inhibits the enzyme thrombin, though it is less effective than other anticoagulants.
When to interrupt dosage
The suggested dose of Lonox is contingent upon the diagnosed condition, such as Deep Vein Thrombosis, Immobility and Outpatients. The measure additionally fluctuates as indicated by the technique of administration featured in the table beneath.Condition
Dosage
Administration
Deep Vein Thrombosis
, 400.0 mg/mL, 600.0 mg/mL, 800.0 mg/mL, 300.0 mg/mL, 100.0 mg/mL, 1200.0 mg/mL, 150.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 900.0 mg/mL
Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Subcutaneous, Injection - Subcutaneous, Solution - Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous
Outpatients
, 400.0 mg/mL, 600.0 mg/mL, 800.0 mg/mL, 300.0 mg/mL, 100.0 mg/mL, 1200.0 mg/mL, 150.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 900.0 mg/mL
Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Subcutaneous, Injection - Subcutaneous, Solution - Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous
General Surgery
, 400.0 mg/mL, 600.0 mg/mL, 800.0 mg/mL, 300.0 mg/mL, 100.0 mg/mL, 1200.0 mg/mL, 150.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 900.0 mg/mL
Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Subcutaneous, Injection - Subcutaneous, Solution - Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous
Ischemia
, 400.0 mg/mL, 600.0 mg/mL, 800.0 mg/mL, 300.0 mg/mL, 100.0 mg/mL, 1200.0 mg/mL, 150.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 900.0 mg/mL
Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Subcutaneous, Injection - Subcutaneous, Solution - Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous
Myocardial Infarction
, 400.0 mg/mL, 600.0 mg/mL, 800.0 mg/mL, 300.0 mg/mL, 100.0 mg/mL, 1200.0 mg/mL, 150.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 900.0 mg/mL
Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Subcutaneous, Injection - Subcutaneous, Solution - Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous
Inpatients
, 400.0 mg/mL, 600.0 mg/mL, 800.0 mg/mL, 300.0 mg/mL, 100.0 mg/mL, 1200.0 mg/mL, 150.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 900.0 mg/mL
Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Subcutaneous, Injection - Subcutaneous, Solution - Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous
Immobility
, 400.0 mg/mL, 600.0 mg/mL, 800.0 mg/mL, 300.0 mg/mL, 100.0 mg/mL, 1200.0 mg/mL, 150.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 900.0 mg/mL
Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Subcutaneous, Injection - Subcutaneous, Solution - Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous
Acute Chest Syndrome
, 400.0 mg/mL, 600.0 mg/mL, 800.0 mg/mL, 300.0 mg/mL, 100.0 mg/mL, 1200.0 mg/mL, 150.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 900.0 mg/mL
Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Subcutaneous, Injection - Subcutaneous, Solution - Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous
Angioplasty
, 400.0 mg/mL, 600.0 mg/mL, 800.0 mg/mL, 300.0 mg/mL, 100.0 mg/mL, 1200.0 mg/mL, 150.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 900.0 mg/mL
Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Subcutaneous, Injection - Subcutaneous, Solution - Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous
Angina, Unstable
, 400.0 mg/mL, 600.0 mg/mL, 800.0 mg/mL, 300.0 mg/mL, 100.0 mg/mL, 1200.0 mg/mL, 150.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 900.0 mg/mL
Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Subcutaneous, Injection - Subcutaneous, Solution - Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous
Warnings
Lonox has six contraindications and should not be taken simultaneously with the ailments noted in the subsequent table.Lonox ContraindicationsCondition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Heparin Induced Thrombocytopenia (HIT)
Do Not Combine
Hemorrhage
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Low Platelet Count
Do Not Combine
Common Lonox Drug Interactions
Drug Name
Risk Level
Description
Albutrepenonacog alfa
Major
The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Enoxaparin.
Andexanet alfa
Major
The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Enoxaparin.
Anti-inhibitor coagulant complex
Major
The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Enoxaparin.
Antihemophilic factor (recombinant), PEGylated
Major
The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Enoxaparin.
Antihemophilic factor human
Major
The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Enoxaparin.
Lonox Toxicity & Overdose RiskThe lowest toxic dose of enoxaparin in mice is greater than 5000mg/kg if given orally and greater than 2500mg/kg if given subcutaneously. If someone has an accidental overdose of enoxaparin, they may experience bleeding. To counteract the overdose, a 1% protamine sulfate solution should be used intravenously in an amount equal to that of the enoxaparin dose. However, if at least 12 hours have passed since the last enoxaparin dose, protamine may not be necessary. It is important to not give too much protamine as it can be fatal.
Lonox Novel Uses: Which Conditions Have a Clinical Trial Featuring Lonox?
76 active clinical trials are currently underway to assess the potential of Lonox in providing relief from Immobility, Acute Chest Syndrome and Outpatient Care.Condition
Clinical Trials
Trial Phases
Acute Chest Syndrome
1 Actively Recruiting
Not Applicable
Immobility
0 Actively Recruiting
General Surgery
1 Actively Recruiting
Not Applicable
Deep Vein Thrombosis
17 Actively Recruiting
Phase 4, Phase 3, Not Applicable, Phase 1, Phase 2
Outpatients
1 Actively Recruiting
Not Applicable
Myocardial Infarction
0 Actively Recruiting
Ischemia
0 Actively Recruiting
Angina, Unstable
0 Actively Recruiting
Inpatients
2 Actively Recruiting
Not Applicable, Phase 2
Angioplasty
8 Actively Recruiting
Phase 3, Phase 4, Not Applicable, Phase 1, Phase 2
Lonox Reviews: What are patients saying about Lonox?
5Patient Review
2/6/2009 While I still sometimes get episodes of IBS, this medication has helped to slow them down and reduce the frequency with which they occur.
5Patient Review
8/21/2008 This drug completely changed my life for the better. I was diagnosed with west nile virus and within a month or two, I could barely leave my house because of how often I needed to use the restroom. This medication allowed me to live a normal life again and I will forever be grateful.
5Patient Review
7/29/2008 I was diagnosed with ulcerative colitis and, as a result, have to deal with diarrhea for the rest of my life. Lonox has been an absolute godsend; it's cut down my "bathroom time" significantly.
5Patient Review
6/23/2009 This pill has been an absolute life-changer for me. I no longer have to worry about finding a bathroom when I'm away from home or risk having an accident.
5Patient Review
4/6/2008 For someone who has dealt with IBS for over a decade, this medication is truly a lifesaver. It's helped to regulate my bowel movements so that instead of going all day long, I only have to go in the morning.
5Patient Review
10/15/2010 These pills have been a wonder for my chronic diarrhea. I'm HIV+ and also have Hep C, so this has been a huge help in managing my symptoms and living a somewhat normal life.
5Patient Review
2/10/2012 This is the only medication that has been effective in treating my diarrhea.
5Patient Review
10/17/20074.7Patient Review
12/12/2009 This medication has been extremely helpful in managing my IBS and possible Crohn's disease. It allows me to have a much better quality of life by being able to leave the house without worry.
4Patient Review
11/24/20073.3Patient Review
8/8/2009 I experienced some pretty intense side effects when I first started taking this medication. dizziness, blurred vision, and nausea were all common for me. I discontinued use after only five days. It took a full three weeks for the medicine to completely clear out of my system.
Patient Q&A Section about lonox
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What is Lonox used for?
"This medication is used to treat diarrhea. It helps to decrease the number and frequency of bowel movements by slowing the movement of the intestines. Diphenoxylate is similar to opioid pain relievers, but it acts mainly to slow the gut."
Answered by AI
Does diphenoxylate Atrop get you high?
"However, when diphenoxylate is taken in high doses, it can cause euphoria and physical dependence like other narcotics. To prevent people from abusing diphenoxylate for its mood-elevating effects, atropine is added to it in small quantities."
Answered by AI
What is diphenoxylate used to treat?
"Diphenoxylate and atropine combination is used to treat severe diarrhea, along with other measures such as fluid and electrolyte treatment. Diphenoxylate helps to stop diarrhea by slowing down the movements of the intestines."
Answered by AI
Is Lonox a controlled substance?
"A healthcare provider may prescribe Lomotil for diarrhea associated with irritable bowel syndrome (IBS) or other digestive diseases or conditions. Lomotil is a controlled substance and is chemically related to a narcotic."
Answered by AI